Vaccine protection against SIVmac239 acquisition

Mauricio A. Martins, Georg F. Bischof, Young C. Shin, William A. Lauer, Lucas Gonzalez-Nieto, David I. Watkins, Eva G. Rakasz, Jeffrey D. Lifson, Ronald C. Desrosiers

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The biological characteristics of HIV pose serious difficulties for the success of a preventive vaccine. Molecularly cloned SIVmac239 is difficult for antibodies to neutralize, and a variety of vaccine approaches have had great difficulty achieving protective immunity against it in rhesus monkey models. Here we report significant protection against i.v. acquisition of SIVmac239 using a long-lasting approach to vaccination. The vaccine regimen includes a replication-competent herpesvirus engineered to contain a near-full-length SIV genome that expresses all nine SIV gene products, assembles noninfectious SIV virion particles, and is capable of eliciting long-lasting effector-memory cellular immune responses to all nine SIV gene products. Vaccinated monkeys were significantly protected against acquisition of SIVmac239 following repeated marginal dose i.v. challenges over a 4-month period. Further work is needed to define the critical components necessary for eliciting this protective immunity, evaluate the breadth of the protection against a variety of strains, and explore how this approach may be extended to human use.

Original languageEnglish (US)
Pages (from-to)1739-1744
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number5
StatePublished - Jan 29 2019


  • AIDS vaccine
  • DNA electroporation
  • HIV
  • Recombinant herpesvirus
  • SIV

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Vaccine protection against SIVmac239 acquisition'. Together they form a unique fingerprint.

Cite this